MinorSecond-generation antihistamine×Antiepileptic – selective sodium channel modulator
Updated · Methodology
Mechanism
The liver does not metabolise fexofenadine, so it does not interact with other drugs through hepatic mechanisms. It is probably excreted mainly in the bile, and up to 10% of a dose is excreted unchanged in the urine (fexofenadine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Inhibitors and inducers of the transporter P-glycoprotein (P-gp) change fexofenadine levels: erythromycin and ketoconazole raise them 2–3 times (fexofenadine SmPC, AEMPS). Lacosamide is eliminated mainly by the kidneys, and its metabolite is formed by CYP3A4, CYP2C9 and CYP2C19. Intestinal P-gp does not transport lacosamide, and the documents do not list it among substances that change P-gp activity (Vimpat SmPC, European Medicines Agency, EMA; Vimpat label, US Food and Drug Administration, FDA). Lacosamide prolongs the PR interval and is used with caution with drugs that affect cardiac conduction (Vimpat SmPC, EMA). Fexofenadine did not change the QTc interval even at high doses and had no effect on cardiac potassium channels (fexofenadine SmPC, AEMPS).
Symptoms
The documents describe no symptoms linked to this combination. In clinical trials, fexofenadine caused headache, somnolence, dizziness and nausea as often as placebo, and objective tests found no significant effect on central nervous system function (fexofenadine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The most frequent adverse effects of lacosamide are dizziness, headache, nausea and double vision. Lacosamide prolongs the PR interval on the electrocardiogram (ECG), and atrioventricular block, bradycardia and other arrhythmias have been reported after marketing (Vimpat SmPC, European Medicines Agency, EMA).
Management
According to the documents, the combination is acceptable, and the doses of fexofenadine and lacosamide need no change. No document names the pair, and lacosamide is not among the substances that change fexofenadine levels through P-glycoprotein (P-gp). Fexofenadine does not belong to the groups of drugs affecting cardiac conduction that call for caution with lacosamide (fexofenadine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; Vimpat SmPC, European Medicines Agency, EMA). Lacosamide is used with caution in people with conduction disorders or severe heart disease. In these patients, an electrocardiogram (ECG) should be considered before the dose is raised above 400 mg per day and after titration to steady state (Vimpat SmPC, EMA). People with heart disease should be warned that antihistamines can cause tachycardia and palpitations (fexofenadine SmPC, AEMPS). Patients should not drive until they know how lacosamide affects them. Dizziness from lacosamide raises the risk of falls (Vimpat SmPC, EMA). Fexofenadine is unlikely to affect driving, but patients should check their own response before driving or doing complex tasks (fexofenadine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Lacosamida (EU/1/08/470), sección 4.5 (2026)– EMA, Vimpat 100 mg comprimidos recubiertos con película (UCB Pharma, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08470005, consultada 03.11.2026, sin fecha de revisión en CIMA, secciones 4.1, 4.3, 4.4, 4.5, 4.7, 4.8 y 5.2
- FDA: Vimpat (lacosamide) prescribing information (2026)– FDA, DailyMed, UCB, Inc., setid 9e79b42c-38a3-4b2c-a196-a5a1948250e2, v63, 05/2026, sections 4, 5.2, 5.3, 7.2, 8.2 and 12.3
- AEMPS: Ficha técnica: Fexofenadina, Fexofenadina Opella 180 mg (nº registro 61911), sección 4.5 (2026)– AEMPS, CIMA, nº registro 61911 (Fexofenadina Opella 180 mg comprimidos recubiertos con película, Opella Healthcare Spain), revisión 04/2026, secciones 4.4, 4.5, 4.7, 4.8, 5.1 y 5.2